Influence of UGT1A1 gene methylation level in colorectal cancer cells on the sensitivity of the chemotherapy drug CPT-11

Biomedicine and Pharmacotherapy

Volumn 68, Issue 7, 2014, Pages 825-831

  Xie, Fang Wei ^a,b,c,d   Peng, Yong Hai ^a   Wang, Wen Wu ^a   Chen, Xi ^a   Chen, Xiong ^a   Li, Jie ^a   Yu, Zong Yang ^a   Ouyang, Xue Nong ^a,b,c,d  

^a FUZHOU GENERAL HOSPITAL   (China)

^b XIAMEN UNIVERSITY   (China)

^c FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

Author keywords

Chemotherapy resistance; Colorectal cancer; CPT 11; Methylation; UGT1A1 gene

Indexed keywords

CES2 PROTEIN; GLUCURONOSYLTRANSFERASE 1A1; GUSB PROTEIN; IRINOTECAN; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOXYLESTERASE; CES2 PROTEIN, HUMAN; GLUCURONOSYLTRANSFERASE; UGT1A1 ENZYME;

ARTICLE; CANCER CELL; CHEMOSENSITIVITY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DEMETHYLATION; DRUG CYTOTOXICITY; EPIGENETICS; GENETIC CORRELATION; HUMAN; HUMAN CELL; IC50; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN METHYLATION; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; DNA METHYLATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARBOXYLESTERASE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HCT116 CELLS; HT29 CELLS; HUMANS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84909645535     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.08.012     Document Type: Article

References (27)

1. Noguchi T., Tanimoto K., Shimokuni T., et al. Aberrant methylation of dpyd promoter, dpyd expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res 2004, 10:7100-7107.
2. Wijermans P., Lübbert M., Verhoef G., et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000, 18:956.
3. David G.L., Yegnasubramanian S., Kumar A., et al. Mdr1 promoter hypermethylation in mcf-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-aza-cytidine. Cancer Biol Ther 2004, 3:537-545.
4. Asano T., Nakamura K., Fujii H., et al. Altered expression of topoisomerase iiα contributes to cross-resistant to etoposide k562/mx2 cell line by aberrant methylation. Br J Cancer 2005, 92:1486-1492.
5. Xie F., Peng Y., Chen X., et al. Relationship between the expression of CES2, UGT1A1, and GUSB in colorectal cancer tissues and aberrant methylation. Neoplasma 2013, 61:99-109.
6. Ohtsuka K., Inoue S., Kameyama M., et al. Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer. Lung Cancer 2003, 41:187-198.
7. Sanghani S.P., Quinney S.K., Fredenburg T.B., et al. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. Clin Cancer Res 2003, 9:4983-4991.
8. Xu G., Zhang W., Ma M.K., et al. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 2002, 8:2605-2611.
9. Tobin P., Clarke S., Seale J.P., et al. The in vitro metabolism of irinotecan (cpt-11) by carboxylesterase and β-glucuronidase in human colorectal tumours. Br J Clin Pharmacol 2006, 62:122-129.
10. Worm J., Kirkin A.F., Dzhandzhugazyan K.N., et al. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J Biol Chem 2001, 276:39990-40000.
11. Hansen L., Thykjaer T., Ørntoft T.F., et al. The role of mismatch repair in small cell lung cancer cells. Eur J Cancer 2003, 39:1456-1467.
12. Akada M., Crnogorac-Jurcevic T., Lattimore S., et al. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of bnip3 in pancreatic cancer. Clin Cancer Res 2005, 11:3094-3101.
13. Ahmad I., Rao DN: Chemistry and biology of DNA methyltransferases. Crit Rev Biochem Mol Biol 1996, 31:361-380.
14. Gagnon J.F., Bernard O., Villeneuve L., et al. Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin Cancer Res 2006, 12:1850-1858.
15. Cai X., Cao W., Ding H., et al. Analysis of UGT1A1* 28 genotype and sn-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai. J Cancer Res Clin Oncol 2013, 139:1579-1589.
16. Natsume A., Ishii D., Wakabayashi T., et al. Ifn-β downregulates the expression of DNA repair gene mgmt and sensitizes resistant glioma cells to temozolomide. Cancer Res 2005, 65:7573-7579.
17. Fisher M.B., VandenBranden M., Findlay K., et al. Tissue distribution and interindividual variation in human udp-glucuronosyltransferase activity: Relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenet Genom 2000, 10:727-739.
18. Feinberg A.P., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts 1983.
19. CÔté J.F., Kirzin S., Kramar A., et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007, 13:3269-3275.
20. Minami H., Sai K., Saeki M., et al. Irinotecan pharmacokinetics/pharmacodynamics and ugt1a genetic polymorphisms in japanese: roles of UGT1A1* 6 and* 28. Pharmacogenet Genom 2007, 17:497-504.
21. Ostanek B., Furlan D., Mavec T., et al. UGT1A1 promoter polymorphism-a new case of a (ta)8allele in caucasians. Blood Cells Mol Dis 2007, 38:78-82.
22. Chen S., Yueh M.-F., Bigo C., et al. Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (cpt-11). Proc Natl Acad Sci 2013, 110:19143-19148.
23. Palii S.S., Van Emburgh B.O., Sankpal U.T., et al. DNA methylation inhibitor 5-aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3b. Mol Cell Biol 2008, 28:752-771.
24. Coral S., Sigalotti L., Covre A., et al. 5-aza-2'-deoxycytidine in cancer immunotherapy: a mouse to man story. Cancer Res 2007, 67:2900.
25. Laird P.W., Jackson-Grusby L., Fazeli A., et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995, 81:197.
26. Santini V., Kantarjian H.M., Issa J.P. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001, 134:573.
27. Plumb J.A., Strathdee G., Sludden J., et al. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hmlh1 gene promoter. Cancer Res 2000, 60:6039-6044.